Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease.

Elizabeth A SpencerSuzannah BergsteinMichael Todd DolingerNanci PittmanAmelia KellarDavid DunkinMarla C Dubinsky

Published in: Inflammatory bowel diseases (2023)

While awaiting pediatric registration trials, our data suggest that UPA is effective in inducing and maintaining SF-CR in adolescents with highly-refractory IBD with an acceptable safety profile.

Keyphrases

young adults
physical activity
ulcerative colitis
big data
data analysis